Orexo R&D Day 2026
A day for investors, analysts and media
During the day, CEO Nikolaj Sørensen and the management team outlined Orexo’s updated strategy and R&D priorities following the divestment of Zubsolv® in the US, including how the company’s proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The program also featured expert perspectives from Mark A. Smith, PhD, Davidson College, NC, US, on emerging threats linked to xylazine, medetomidine, and fentanyl combinations.
Link to event: https://investorcaller.com/events/orexo/orexo-rd-day-march-24-2026
